According to the announcement of Xingqi Pharmaceutical, the company plans to use its own funds and special loan funds for stock repurchase to repurchase shares through centralized bidding transactions to cancel and reduce registered capital. The repurchase capital is not less than 80 million yuan and no more than 100 million yuan, and the repurchase price is not more than 58 yuan/share. It is estimated that 1,379,300 to 1,7241 thousand shares will be repurchased, accounting for 0.39%-0.48% of the total share capital. The implementation period shall not exceed 12 months from the date of review and approval by the shareholders' meeting. Furthermore, there are risks such as not being able to implement this repurchase or only partially implementing it.

According to the announcement of Xingqi Pharmaceutical, the company plans to use its own funds and special loan funds for stock repurchase to repurchase shares through centralized bidding transactions to cancel and reduce registered capital. The repurchase capital is not less than 80 million yuan and no more than 100 million yuan, and the repurchase price is not more than 58 yuan/share. It is estimated that 1,379,300 to 1,7241 thousand shares will be repurchased, accounting for 0.39%-0.48% of the total share capital. The implementation period shall not exceed 12 months from the date of review and approval by the shareholders' meeting. Furthermore, there are risks such as not being able to implement this repurchase or only partially implementing it.